NASDAQ:PYXS Pyxis Oncology (PYXS) Stock Price, News & Analysis $1.92 -0.06 (-2.78%) As of 11:08 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Pyxis Oncology Stock (NASDAQ:PYXS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Pyxis Oncology alerts:Sign Up Key Stats Today's Range$1.92▼$1.9950-Day Range$1.68▼$3.8952-Week Range$1.03▼$5.55Volume115,920 shsAverage Volume905,864 shsMarket Capitalization$160.56 millionP/E RatioN/ADividend YieldN/APrice Target$8.75Consensus RatingModerate Buy Company Overview Pyxis Oncology, Inc. is a clinical-stage biotechnology company focused on developing antibody-based therapies for the treatment of cancer. The company aims to address limitations of existing cancer treatments by designing therapeutics intended to selectively target tumors and activate the immune system while minimizing effects on healthy tissue. Pyxis Oncology’s pipeline includes antibody-drug conjugates and immunotherapies designed to act on targets in the tumor microenvironment. Its lead programs have included PYX-201, an antibody-drug conjugate intended to deliver a cytotoxic payload to tumors expressing the fibronectin extra domain-B target, and other investigational antibody-based programs directed at immune-suppressive pathways. These products remain investigational and are being evaluated in clinical development; the company does not have an approved commercial product. Founded in 2019 and headquartered in Boston, Massachusetts, Pyxis Oncology conducts its research and clinical development activities primarily through operations in the United States. The company was formed with support from biotechnology investors and became a publicly traded company on the Nasdaq exchange in 2021. Pyxis Oncology is led by Lara Sullivan, M.D., who serves as president and chief executive officer.AI Generated. May Contain Errors. Read More Pyxis Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScorePYXS MarketRank™: 3.54765897072 of 5 starsPyxis Oncology scored higher than 71% of companies evaluated by MarketBeat, and ranked 180th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingPyxis Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on no strong buy ratings, 8 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialPyxis Oncology has a consensus price target of $8.75, representing about 351.0% upside from its current price of $1.94.Amount of Analyst CoveragePyxis Oncology has only been the subject of 4 research reports in the past 90 days.Read more about Pyxis Oncology's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Pyxis Oncology are expected to grow in the coming year, from ($1.21) to ($1.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pyxis Oncology is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pyxis Oncology is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPyxis Oncology has a P/B Ratio of 2.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Pyxis Oncology's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.53% of the float of Pyxis Oncology has been sold short.Short Interest Ratio / Days to CoverPyxis Oncology has a short interest ratio ("days to cover") of 3.47, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pyxis Oncology has recently decreased by 11.06%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPyxis Oncology does not currently pay a dividend.Dividend GrowthPyxis Oncology does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.29 News SentimentPyxis Oncology has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Pyxis Oncology this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for PYXS on MarketBeat in the last 30 days. This is a decrease of -82% compared to the previous 30 days.MarketBeat Follows2 people have added Pyxis Oncology to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Pyxis Oncology insiders have not sold or bought any company stock.Percentage Held by Insiders5.70% of the stock of Pyxis Oncology is held by insiders.Percentage Held by Institutions39.07% of the stock of Pyxis Oncology is held by institutions.Read more about Pyxis Oncology's insider trading history. Receive PYXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pyxis Oncology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PYXS Stock News HeadlinesPyxis Oncology, Inc. (NASDAQ:PYXS) Stock Has Average Target Price of $8.75October 29 at 2:14 AM | americanbankingnews.comPyxis Oncology to Participate in Upcoming Investor ConferencesOctober 28 at 7:30 AM | globenewswire.comYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners guide...please take a few seconds and download it right now before your download link expires. That way, no matter what it costs in the future, you'll have a free copy on your computer.October 29 at 1:00 AM | Profits Run (Ad)Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on ...October 27 at 12:41 PM | markets.businessinsider.comPyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsOctober 27 at 8:45 AM | globenewswire.comPyxis Oncology (PYXS) Projected to Announce Earnings on MondayOctober 26 at 5:13 AM | americanbankingnews.comPyxis: Downgrading To 'Hold' After PYX-106 Dropped And Continued HNSCC Advancement MICVOOctober 23, 2026 | seekingalpha.comPyxis Oncology (PYXS) Receives a Buy from Wells FargoOctober 20, 2026 | theglobeandmail.comSee More Headlines PYXS Stock Analysis - Frequently Asked Questions How have PYXS shares performed this year? Pyxis Oncology's stock was trading at $1.15 at the beginning of the year. Since then, PYXS stock has increased by 68.7% and is now trading at $1.94. How were Pyxis Oncology's earnings last quarter? Pyxis Oncology, Inc. (NASDAQ:PYXS) released its quarterly earnings data on Thursday, August, 13th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.35) by $0.05. When did Pyxis Oncology IPO? Pyxis Oncology (PYXS) raised $158 million in an IPO on Wednesday, October 6th 2021. The company issued 10,500,000 shares at a price of $14.00-$16.00 per share. Who are Pyxis Oncology's major shareholders? Pyxis Oncology's top institutional investors include T3 Companies LLC (0.03%). Insiders that own company stock include Pamela Ann Connealy and Rachel Humphrey. View institutional ownership trends. How do I buy shares of Pyxis Oncology? Shares of PYXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pyxis Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pyxis Oncology investors own include NVIDIA (NVDA), Iovance Biotherapeutics (IOVA), Palantir Technologies (PLTR), Viking Therapeutics (VKTX), Voyager Therapeutics (VYGR), Micron Technology (MU) and Nkarta (NKTX). Company Calendar Last Earnings8/13/2026Today10/29/2026Next Earnings (Estimated)11/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (9m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 PYXS's financial health is in the Green zone, according to TradeSmith. PYXS has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PYXS CIK1782223 Webwww.pyxisoncology.com Phone617-221-9059FaxN/AEmployees56Year Founded2019Price Target and Rating Average Price Target for Pyxis Oncology$8.75 High Price Target$19.00 Low Price Target$5.00 Potential Upside/Downside+354.5%Consensus RatingModerate Buy Rating Score (0-4)2.70 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($1.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$79.62 million Net MarginsN/A Pretax Margin-793.84% Return on Equity-215.23% Return on Assets-112.19% Debt Debt-to-Equity RatioN/A Current Ratio1.34 Quick Ratio1.34 Sales & Book Value Annual Sales$11.04 million Price / Sales14.55 Cash FlowN/A Price / Cash FlowN/A Book Value$0.86 per share Price / Book2.24Miscellaneous Outstanding Shares83,408,000Free Float78,654,000Market Cap$160.56 million OptionableOptionable Beta1.37 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:PYXS) was last updated on 10/29/2026 by MarketBeat.com Staff. From Our PartnersA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Withou...Behind the Markets | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe "velvet rope" stock setups hiding from regular indicatorsK.I.R.A. is a new trading engine built to flag market setups before they show up on standard charts. Former...The TradingPub | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredElon Musk's Intel Deal Already Jumped 177 Percent This YearElon Musk's April 2026 partnership with Intel sent shares climbing 177% within two months. Jeff Brown, the ...Brownstone Research | SponsoredThe Claude AI company doubled in value... you missed itIn May, Anthropic raised money at a $965 billion valuation. Now, ahead of its IPO, investors are reportedly di...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pyxis Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pyxis Oncology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
